Chelsea Kotch

6PUBLICATIONS
6CO-AUTHORS
Molecular targetsNeurology and neuromuscular diseasesPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Apr 30, 2026
MEK inhibitors for neurofibromatosis type 1-associated central and peripheral nervous system tumors.

|Apr 29, 2025
Location and extent of disease predicts outcome of neurofibromatosis type 1-related pediatric low-grade gliomas.

Sneha M Chaturvedi, Arohi Saxena, Ahmad Hassan

|Oct 06, 2023
The impact of changes in gadolinium-enhancement on disease progression in children with neurofibromatosis type 1-associated optic pathway glioma: a retrospective analysis.

Chelsea Kotch, Stephanie J Si, Kavita Desai

|May 13, 2023
Vinblastine/Methotrexate for Debilitating and Progressive Plexiform Neurofibroma in Children and Young Adults with Neurofibromatosis Type 1: A Phase 2 Study.

Chelsea Kotch, Kristina Wagner, J Harris Broad

|Jan 12, 2022
Risk factors for treatment-refractory and relapsed optic pathway glioma in children with neurofibromatosis type 1.

Chelsea Kotch, Robert Avery, Kelly D Getz

|Jun 21, 2019
Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome.

Chelsea Kotch, David Barrett, David T Teachey

Pageof 1

Frequent Collaborators

1 joint publications

Eric Bouffet

1 joint publications

Jane E Minturn

1 joint publications

Katherine Smith

1 joint publications

Michael J Fisher